BUSINESS

J-TEC’s Cell Sheet JACE Filed for Epidermolysis Bullosa

March 23, 2018
Japan Tissue Engineering (J-TEC) said on March 22 that it has filed an application seeking an additional indication for JACE, an autologous cultured epidermis, for the treatment of epidermolysis bullosa.J-TEC, a Fujifilm Group company, first received approval for JACE in…

To read the full story

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Tatsuya Otsuka

The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…